Tag Archives: Medicare Part D

The Sovaldi Case: Is American Biotech History About to Repeat Itself?

Recent Congressional investigations over the pricing scheme of Gilead’s much-heralded hepatitis C drug Sovaldi – and a decline in stocks across the biotech sector – rings a familiar bell, writes Tom Norton. Twenty years ago in May, US Senator Joe Lieberman carefully questioned biotech CEO Harry Penner of then Neurogen Corporation about why his company’s […]
Posted in Biotech, healthcare, leadership, Market Access, pricing, R&D, Sales, Strategy | Also tagged , , , , , , , , | 2 Comments

"Close Call" for American Rx Marketers on Medicare Part D

As the U.S. heads towards a public market place in which Medicare, Medicaid, CHIPs, VA, and now Obamacare will shortly comprise almost 70% of the American healthcare market, American Rx marketers recently endured a “close call” with the U.S. Department of Health and Human Services over the arbitrary deletion of dozens of key drugs from […]
Posted in Marketing, Op-Ed, Regulatory | Also tagged , , , | Leave a comment

Obama Administration Halts Attack on Medicare Drug Plans

In an abrupt about-face, the Obama administration halted its ill-timed effort to launch an overhaul of the Medicare Part D program and announced it would not pursue changes in some key rules as proposed earlier this year. CMS had issued a proposed rule January 10 to drop “protected” class status for antidepressants and immunosuppressants in […]
Posted in FDA, healthcare, Legal, Market Access | Also tagged , , , , , , | Leave a comment

Medicare “Wasting Billions of Dollars”, Says Study

Waste to Taxpayers detected in Medicare Part D Plan, Poorer people are being prescribed more expensive branded drugs. Is that bad? According to a new investigation it is.  And it is costing the taxpayers a shovel-load of money.  And furthermore,  it’s unnecessary. The failure of the government to track doctors who prescribe cheaper generics for […]
Posted in healthcare | Also tagged , | Leave a comment

Feds Take a Pass on Co-Pay Offsets Under Obamacare

Feds Take a Pass on Co-Pay Offsets Under Obamacare The implosion of the Affordable Care Act’s vaunted healthcare.gov benefit enrollment process has obscured a far more critical issue for big Pharma:  how much leeway do companies have in promoting durable brand affiliations among the potentially millions of new patients with subsidized access to new  medicines? […]
Posted in healthcare, Regulatory | Also tagged , , , , | Leave a comment
  • Categories

  • Meta